Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tecarfarin - Espero BioPharma

Drug Profile

Tecarfarin - Espero BioPharma

Alternative Names: ATI-5000; ATI-5923

Latest Information Update: 15 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ARYx Therapeutics
  • Developer Espero BioPharma; Lee's Pharmaceutical
  • Class Anticoagulants; Antithrombotics; Small molecules; Vascular disorder therapies
  • Mechanism of Action Vitamin K epoxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thromboembolism
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Thromboembolism; Thrombosis

Most Recent Events

  • 11 Mar 2019 Tecarfarin receives Orphan Drug status for Thromboembolism (Prevention) in USA
  • 24 Jun 2018 Biomarkers information updated
  • 22 Jun 2018 Phase-I clinical trials in Thrombosis (In volunteers) in Hong Kong (PO) (NCT03652779)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top